男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Latest

Eli Lilly promotes new drug at CIIE

By SHI JING in Shanghai | chinadaily.com.cn | Updated: 2019-11-09 09:43
Share
Share - WeChat

Indianapolis-headquartered pharmaceutical company Eli Lilly and Company attended the second China International Import Expo with its latest medicine Taltz to moderate severe plaque psoriasis.

During the news conference on Thursday, a total of 17 Chinese domestic pharmaceutical companies signed intention agreements with Eli Lilly for the purchase of Taltz. The medicine has been approved by China's National Products Administration in September.

Eli Lilly and Company was not present at last year's CIIE. Julio Gay-Ger, president and general manager of Lilly China, said that they "were positively surprised by the huge success that CIIE had last year".

"So we really want to be part of the CIIE in the second year. We have had in the last 12 months five new molecular entities launched in China. This is very close to our record. More importantly, we have up to 40 new launches in the next seven to 10 years. We are bringing innovations to Chinese patients which will make a huge difference to them," he said.

Gay-Ger said the company has had expectations for Lilly China's sales and business growth.

"China is the second-largest pharmaceutical market in the world today. It is supposed to be the No 1 pharmaceutical market in the future. It is our top priority market and that is why we are investing so heavily and bringing so much innovation here," he said.

Lilly set up its Shanghai office in 1918, which was the first overseas office for the US pharmaceutical company. Lilly China's overall growth rate for the first half of 2019 exceeded 30 percent, reaching a record high throughout the company's 101-year history in China.

Ever since 2013, Lilly has invested about $320 million to build an insulin production facility in Suzhou. The site is set to be an integral part of Lilly's global supply chain, providing insulin products for China, Europe and other markets across the world in 2019.

"In the future, we can have new launches in China simultaneously or almost simultaneously with other markets in the world. That progress is in part because of the great reform that government is taking, which offers great opportunity to have all that happen," he said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 高安市| 白银市| 陇西县| 道孚县| 泗阳县| 磐安县| 琼中| 两当县| 安阳市| 谢通门县| 婺源县| 平原县| 明光市| 板桥市| 利川市| 桑植县| 弥勒县| 梅河口市| 霍山县| 格尔木市| 尉犁县| 长子县| 禹州市| 金阳县| 松桃| 故城县| 海盐县| 广饶县| 龙州县| 县级市| 韩城市| 墨江| 三都| 南岸区| 密山市| 运城市| 那曲县| 唐山市| 普宁市| 仙居县| 新龙县|